Stoke Therapeutics presents preclinical data from studies of STK-001
Stoke Therapeutics announced preclinical data from studies of STK-001 "that showed significant improvements in survival and reductions in seizure frequency in a mouse model of Dravet syndrome." New data from electroencephalography recordings showed 76% of DS mice treated with STK-001 were seizure free compared to 48% that were treated with a placebo, the company said in a statement. An 80% reduction in the average number of spontaneous seizures was also observed among treated DS mice compared to placebo. These data were presented in a poster session at the American Epilepsy Society Annual Meeting in Baltimore. "The data on STK-001 from this mouse model give us confidence in our approach to treating the underlying cause of Dravet syndrome by restoring Nav1.1 protein expression to near normal levels," said Edward Kaye, Chief Executive Officer of Stoke Therapeutics. "The reductions in mortality previously observed with STK-001 were compelling and the new EEG data provide further evidence of the potential for STK-001 to impact Dravet syndrome by reducing seizure frequency and possibly preventing seizures entirely. What is particularly remarkable is that these data were generated from a spontaneous seizure model, which we believe accurately reflects the clinical situation in people with Dravet syndrome."